UroTrials GmbH
- Address
- Sedanstrasse 15, Zellerau
Sponsor Overview
Specializations
Prostate Cancer Therapeutics
UroTrials GmbH focuses on metastatic castrate-sensitive prostate cancer, targeting advanced disease management.
- Androgen receptor pathway inhibition
- Androgen receptor degradation
- Optimization of PSA response
The program integrates androgen deprivation therapy with emerging agents to enhance treatment outcomes.
Biomarker and Response Assessment
The sponsor prioritizes quantitative monitoring of prostate-specific antigen dynamics as a key efficacy metric.
- Serial PSA kinetics
- Early treatment-switch decision criteria
- Predictive biomarker exploration
These efforts aim to refine patient selection and therapeutic sequencing in the targeted disease.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Phase II Trial of BMS-986365 Switch in Metastatic Castration-Sensitive Prostate Cancer with Suboptimal PSA Response after ADT and ARPI | Germany | Not Yet Recruiting |
Data & Insights
This sponsor works with 1 molecule, of which 0 are not being studied by other sponsors.
This sponsor has worked with 16 sites across their trial portfolio.
Therapeutic Focus
- 1.Male Urogenital Diseases1 trial111 other sponsors
Partnered Research Centres
16 centres- Address
- Theodor-Stern-Kai 7, 60590 Frankfurt
- Address
- Virchowstraße 47, 42283 Wuppertal
- Address
- Albert-Einstein-Allee 23, Eselsberg, 89081 Ulm
- Address
- Ismaninger Strasse 22, Au-Haidhausen, 81675 Munich
- Address
- Prof.-Ernst-Nathan-Strasse 1, 90419 Nuremberg
- Address
- Ziemssenstrasse 1, Ludwigsvorstadt-Isarvorstadt, 80336 Munich
Want to get in touch with this sponsor?
Send a question and we'll pass it on to UroTrials GmbH.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.

